Bank of Montreal Can lessened its stake in shares of Halyard Health, Inc. (NYSE:HYH) by 50.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,682 shares of the medical instruments supplier’s stock after selling 3,780 shares during the quarter. Bank of Montreal Can’s holdings in Halyard Health were worth $145,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently bought and sold shares of HYH. Meadow Creek Investment Management LLC increased its stake in shares of Halyard Health by 1.1% during the first quarter. Meadow Creek Investment Management LLC now owns 2,660 shares of the medical instruments supplier’s stock valued at $101,000 after acquiring an additional 28 shares during the period. Glen Harbor Capital Management LLC boosted its holdings in Halyard Health by 1.1% during the first quarter. Glen Harbor Capital Management LLC now owns 3,230 shares of the medical instruments supplier’s stock worth $123,000 after buying an additional 34 shares in the last quarter. Victory Capital Management Inc. bought a new stake in Halyard Health during the first quarter worth approximately $153,000. Tower Research Capital LLC TRC boosted its holdings in Halyard Health by 102.5% during the first quarter. Tower Research Capital LLC TRC now owns 4,836 shares of the medical instruments supplier’s stock worth $184,000 after buying an additional 2,448 shares in the last quarter. Finally, Capstone Asset Management Co. bought a new stake in Halyard Health during the first quarter worth approximately $203,000. Institutional investors and hedge funds own 91.02% of the company’s stock.
A number of brokerages recently weighed in on HYH. BidaskClub upgraded shares of Halyard Health from a “hold” rating to a “buy” rating in a report on Saturday, August 19th. Deutsche Bank AG raised their target price on shares of Halyard Health from $35.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, August 3rd. Stephens upgraded shares of Halyard Health from an “equal weight” rating to an “overweight” rating in a report on Thursday, August 3rd. TheStreet upgraded shares of Halyard Health from a “c” rating to a “b” rating in a report on Thursday, June 22nd. Finally, Zacks Investment Research upgraded shares of Halyard Health from a “hold” rating to a “buy” rating and set a $44.00 target price for the company in a report on Wednesday, July 12th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $42.25.
TRADEMARK VIOLATION NOTICE: This article was posted by BBNS and is the property of of BBNS. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://baseballnewssource.com/markets/bank-of-montreal-can-sells-3780-shares-of-halyard-health-inc-hyh/1604341.html.
Halyard Health, Inc. (NYSE:HYH) traded down 0.18% during trading on Friday, reaching $45.50. 178,360 shares of the company were exchanged. The firm has a market cap of $2.12 billion, a price-to-earnings ratio of 43.75 and a beta of 1.76. Halyard Health, Inc. has a 52-week low of $31.59 and a 52-week high of $46.36. The firm has a 50-day moving average of $43.26 and a 200-day moving average of $39.57.
Halyard Health (NYSE:HYH) last issued its earnings results on Wednesday, August 2nd. The medical instruments supplier reported $0.51 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.37 by $0.14. Halyard Health had a net margin of 3.06% and a return on equity of 8.29%. The firm had revenue of $399.20 million during the quarter, compared to the consensus estimate of $399.16 million. During the same quarter in the prior year, the firm earned $0.45 earnings per share. The business’s quarterly revenue was down .2% on a year-over-year basis. On average, equities analysts forecast that Halyard Health, Inc. will post $1.98 EPS for the current year.
About Halyard Health
Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.
Receive News & Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related companies with our FREE daily email newsletter.